Nature Outlook |

Alzheimer’s disease

Alzheimer’s disease is the most common form of dementia. For decades, researchers have sought a treatment to no avail, and our understanding of the condition is now being questioned. This Outlook lays bare the problems, the disagreements and the reasons to be hopeful.

This Nature Outlook is editorially independent. It is produced with third party financial support. About this content.

Features and comment

More from Nature Research

  • Nature Medicine | Review Article

    In this Review, Salter and Stevens discuss the role of microglia in CNS disorders such as autism, neurodegenerative disorders, Alzheimer’s disease, and chronic pain.

    • Michael W Salter
    •  &  Beth Stevens
  • Nature Reviews Neurology | Review Article

    Determining how the incidence and prevalence of dementia changes over time requires population-based studies that use consistent methods over time. In this Review, the authors discuss the results of 14 worldwide studies that have attempted this approach. The findings consistently indicate that the incidence and prevalence of dementia, at least in Western countries, is stable or declining.

    • Yu-Tzu Wu
    • , Alexa S. Beiser
    • , Monique M. B. Breteler
    • , Laura Fratiglioni
    • , Catherine Helmer
    • , Hugh C. Hendrie
    • , Hiroyuki Honda
    • , M. Arfan Ikram
    • , Kenneth M. Langa
    • , Antonio Lobo
    • , Fiona E. Matthews
    • , Tomoyuki Ohara
    • , Karine Pérès
    • , Chengxuan Qiu
    • , Sudha Seshadri
    • , Britt-Marie Sjölund
    • , Ingmar Skoog
    •  &  Carol Brayne
  • Nature Medicine | Editorial

    Therapies for Alzheimer's disease and other neurodegenerative diseases are desperately needed. Yet, a string of disappointments in the neurodegenerative therapy space has meant that several companies over the years have ended their investment in the field. Some companies have diversified their research and development (R&D) models to hedge their bets. Maintaining this diversity to bring down the silos between big pharma and smaller research teams may be necessary to jumpstart and sustain progress in combatting neurodegenerative conditions.

  • Nature Reviews Neurology | Review Article

    Increasing evidence suggests that Alzheimer disease (AD) is not simply a CNS disorder, but involves interactions between systemic and brain-related factors. Wang and colleagues review the role of amyloid-β (Aβ) in AD, highlighting systemic abnormalities linked to Aβ metabolism and discussing how these abnormalities might influence central pathways of Aβ production and clearance.

    • Jun Wang
    • , Ben J. Gu
    • , Colin L. Masters
    •  &  Yan-Jiang Wang
  • Nature Reviews Neuroscience | Opinion

    There has been a surge in the number of papers discussing the idea that inter-neuronal spread of 'pathogenic' proteins contributes to neurodegenerative disease progression. Walsh and Selkoe provide a critical overview of the evidence for this mechanism, identify gaps in our knowledge and suggest experimental approaches to test the hypothesis.

    • Dominic M. Walsh
    •  &  Dennis J. Selkoe